Sol-Gel Technologies Overview
Sol-Gel Technologies is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its current product candidate pipeline consists of late-stage branded product candidates that leverage its proprietary silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. Sol-Gel was successful in developing pioneer topical drugs, Twyneo and Epsolay, for the treatment of acne and inflammatory lesions of rosacea. Both products are marketed in the US by Galderma since 2022. The company is developing topical patidegib that is expected to be approved for the treatment of Gorlin syndrome and topical erlotinib for the treatment of pachyonychia congenita and other rare skin indications.
Cumulative Funding Raised Over Time ($)
$19.0M
$26.0MJun 2006
$35.0MNov 2008
Latest News
growth-negative
סולג'ל של ארקין מוכרת את שתי תרופות הדגל בניסיון לבלום את הקריסה במניה
סולגל, a company developing dermatological drugs, has sold the U.S. marketing rights for its two main products, EPSOLAY and TWYNEO, to the Australian pharmaceutical company Mayne for $16 million. This decision comes after the commercial failure of these products, which contributed to a decline in the companys stock value. The sale aims to fund the development of a new drug for treating skin cancer in patients with the rare Gorlin syndrome. The transaction reflects a strategic move to stabilize the companys financial situation and focus on promising treatments.
Acquisition
growth-positive
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Sol-Gel Technologies, a dermatology company, announced that its partner, Padagis Israel Pharmaceuticals, has submitted a first-to-file Abbreviated New Drug Application (ANDA) to the U.S. FDA for Roflumilast Cream, a generic drug for the treatment of plaque psoriasis. This comes after Arcutis Biotherapeutics initiated a patent infringement action regarding the Padagis Roflumilast Cream. If approved, Sol-Gel and Padagis will share the gross profit from potential sales of the cream. The market sales for the cream were approximately $95 million in the 12 months ended in January 2024.
PartnersInvestment
growth-positive
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
Sol-Gel Technologies Ltd. has announced the initiation of Phase 3 testing for its drug SGT-610, a topical hedgehog inhibitor being developed to prevent new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome. The drug has received Orphan Drug and Breakthrough Therapy designation in the U.S. and E.U. The company anticipates that SGT-610 could have a market potential of over $300 million. The Phase 3 study will involve approximately 140 subjects at around 40 clinical centers in North America, the United Kingdom, and Europe.
Investment
growth-positive
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
Sol-Gel Technologies Ltd., a dermatology company, announced it will host a virtual KOL event on December 6, 2023, to discuss the disease burden of Gorlin syndrome and the therapeutic potential of SGT-610. The event will feature Julie Breneiser, Executive Director of the Gorlin Syndrome Alliance, and Ervin Epstein Jr., MD, Co-Founder of PellePharm Inc. SGT-610, a new hedgehog inhibitor (HHI), is in development to prevent new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome. The drug has been granted Orphan Drug Designation and Breakthrough Designation by the FDA.
InvestmentExpand
growth-positive
Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?
The article discusses the intrinsic value of Sol-Gel Technologies Ltd. using the Discounted Cash Flow (DCF) model. The companys fair value estimate is US$1.87, suggesting it is undervalued by 24% based on its current share price of US$1.41. The DCF model estimates the companys future cash flows and discounts them to their present value. The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value. The article also includes a SWOT analysis for Sol-Gel Technologies.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $146M |
| Last funding | $5M |
| Stage | Public |
| Rounds | 7 |
| Investors | 3 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.sol-gel.com/ |
| Careers | Careers page |
Locations
Golda Meir Street 7, Nes Ziyyona, Israel
Photos & Videos
1 item(s)
Sol-Gel Technologies Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
Materials & SubstancesNanomaterialsBiologicalsTags (12)
pharmaceuticalsdermatologymedicationskin-caretopical-treatmentnanotechnologydrug-deliverychronic-patientsacnelife-sciencescosmetic-companiespharma-companiesGeographic Markets
United StatesEuropeSol-Gel Technologies Financials
$146M
Total funding
Undisclosed
Capital raised
$5M
Last funding
Public
Funding stage
7
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$19.0M
$26.0MJun 2006
$35.0MNov 2008
Private Equity Funding
Undisclosed Round
Nov 2008
$9M
Medica Venture Partners
Undisclosed Round
Jun 2006
$7M
JVP
Undisclosed Round
$19M
Argonaut Ventures
Public Offering / Exit
POEvent
Apr 2020
Undisclosed
POEvent
Feb 2020
Undisclosed
POEvent
Aug 2019
Undisclosed
POEvent
Feb 2018
Undisclosed
MNAEvent
Jul 2014
Undisclosed
Sol-Gel Technologies Lifecycle
Cumulative Funding Raised Over Time
$19.0M
$26.0MJun 2006
$35.0MNov 2008
All Events
Undisclosed Round
Nov 2008
$9M
Medica Venture Partners
Undisclosed Round
Jun 2006
$7M
JVP
Undisclosed Round
$19M
Argonaut Ventures
POEvent
Apr 2020
Undisclosed
POEvent
Feb 2020
Undisclosed
POEvent
Aug 2019
Undisclosed
POEvent
Feb 2018
Undisclosed
MNAEvent
Jul 2014
Undisclosed
Sol-Gel Technologies News
47 articles
growth-negative
סולג'ל של ארקין מוכרת את שתי תרופות הדגל בניסיון לבלום את הקריסה במניה
סולגל, a company developing dermatological drugs, has sold the U.S. marketing rights for its two main products, EPSOLAY and TWYNEO, to the Australian pharmaceutical company Mayne for $16 million. This decision comes after the commercial failure of these products, which contributed to a decline in the companys stock value. The sale aims to fund the development of a new drug for treating skin cancer in patients with the rare Gorlin syndrome. The transaction reflects a strategic move to stabilize the companys financial situation and focus on promising treatments.
Acquisition
growth-positive
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Sol-Gel Technologies, a dermatology company, announced that its partner, Padagis Israel Pharmaceuticals, has submitted a first-to-file Abbreviated New Drug Application (ANDA) to the U.S. FDA for Roflumilast Cream, a generic drug for the treatment of plaque psoriasis. This comes after Arcutis Biotherapeutics initiated a patent infringement action regarding the Padagis Roflumilast Cream. If approved, Sol-Gel and Padagis will share the gross profit from potential sales of the cream. The market sales for the cream were approximately $95 million in the 12 months ended in January 2024.
PartnersInvestment
growth-positive
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
Sol-Gel Technologies Ltd. has announced the initiation of Phase 3 testing for its drug SGT-610, a topical hedgehog inhibitor being developed to prevent new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome. The drug has received Orphan Drug and Breakthrough Therapy designation in the U.S. and E.U. The company anticipates that SGT-610 could have a market potential of over $300 million. The Phase 3 study will involve approximately 140 subjects at around 40 clinical centers in North America, the United Kingdom, and Europe.
Investment
growth-positive
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
Sol-Gel Technologies Ltd., a dermatology company, announced it will host a virtual KOL event on December 6, 2023, to discuss the disease burden of Gorlin syndrome and the therapeutic potential of SGT-610. The event will feature Julie Breneiser, Executive Director of the Gorlin Syndrome Alliance, and Ervin Epstein Jr., MD, Co-Founder of PellePharm Inc. SGT-610, a new hedgehog inhibitor (HHI), is in development to prevent new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome. The drug has been granted Orphan Drug Designation and Breakthrough Designation by the FDA.
InvestmentExpand
growth-positive
Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?
The article discusses the intrinsic value of Sol-Gel Technologies Ltd. using the Discounted Cash Flow (DCF) model. The companys fair value estimate is US$1.87, suggesting it is undervalued by 24% based on its current share price of US$1.41. The DCF model estimates the companys future cash flows and discounts them to their present value. The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value. The article also includes a SWOT analysis for Sol-Gel Technologies.
Investment
growth-positive
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Sol-Gel Technologies Ltd. announced its financial results for Q3 2023 and provided a corporate update. The company is on track to begin Phase 3 testing for its Orphan Drug candidate, SGT-610, for the prevention of basal cell carcinoma in subjects having Gorlin syndrome. The company expects this candidate to have a market potential of over $300 million. Sol-Gel also announced that it continues to have discussions with prospective partners to secure new international licenses for its marketed products, TWYNEO and EPSOLAY. The company reported a net loss of $5.7 million for the third quarter of 2023.
InvestmentExpand
growth-positive
Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies
The article discusses the growth prospects of generic drug manufacturers, focusing on Dr. Reddys Laboratories, Amphastar Pharmaceuticals, and Sol-Gel Technologies. Despite challenges like price erosion due to macroeconomic factors, the volume of existing generic drugs is rising, benefiting these companies. They are also exploring strategic collaborations and focusing on new product launches to expand their market share. The loss of patent exclusivity of branded drugs, stiff competition, and patent settlements are shaping the future of the generic drugs industry. The article also highlights that the Zacks Medical – Generic Drugs industry has outperformed the broader Zacks Medical sector and the S&P 500 Index in the past year.
CustomersPartnersExpand
growth-positive
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
Despite macroeconomic headwinds, the rising volume of existing generic drugs continues to benefit generic drugmakers like Dr. Reddy’s Laboratories, Amphastar Pharmaceuticals, and Sol-Gel Technologies. To further expand market share, these companies are exploring strategic collaborations and focusing on new product launches. The loss of patent exclusivity of branded drugs provides significant opportunities for these generic drugmakers. However, they face stiff competition from original branded drugs and other generic drugmakers. The successful resolution of patent challenges is also an essential catalyst for their growth.
CustomersPartnersExpand
Growth-Negative
Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Invest In Growth?
Sol-Gel Technologies, a biotech company, is experiencing a significant increase in its cash burn rate, which has grown by 274% over the last year. This, coupled with a 96% drop in operating revenue, has raised concerns about the companys future. However, the company had a cash reserve of $47m as of June 2023, giving it a cash runway of 4.1 years. Analysts predict that the company will reach a break-even point before the cash runway ends. The companys market capitalisation is $37m, and it burnt through $11m last year, which is 31% of the companys market value.
Investment
growth-positive
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Sol-Gel Technologies will virtually present at the H.C. Wainwright 25th Annual Global Investment Conference. The company is a dermatology company focused on developing and commercializing drug products for the treatment of skin diseases. They have two approved products, EPSOLAY and TWYNEO, for the treatment of severe skin conditions. Sol-Gels pipeline includes an Orphan Drug candidate and a topical drug candidate. The virtual presentation will be accessible on-demand starting September 11, 2023.
InvestmentPublic Trading
growth-positive
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Sol-Gel Technologies Ltd. has announced its financial results for Q2 2023, revealing a partnership with Searchlight Pharma that will provide up to $11 million in upfront payments and regulatory and sales milestones for both TWYNEO® and EPSOLAY®. The company also plans to advance its Orphan Drug candidate, SGT-610, into Phase 3 testing in late 2023. However, due to lower-than-expected future royalty streams from EPSOLAY and TWYNEO in the U.S., Sol-Gel is focusing on SGT-610 and delaying the planned clinical study for SGT-210. The company is also implementing cost-saving measures, including a reduction of about 25 employees.
PartnersInvestmentLayoffsExpand
growth-negative
Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates
Sol-Gel Technologies Ltd. reported a quarterly loss of $0.22 per share, which is better than the Zacks Consensus Estimate of a loss of $0.26. However, the companys revenues of $0.59 million for the quarter ended June 2023 missed the Zacks Consensus Estimate by 61.68%, compared to year-ago revenues of $3.52 million. The companys shares have lost about 30.7% since the beginning of the year. The companys earnings outlook is currently unfavorable, translating into a Zacks Rank #4 (Sell) for the stock.
Investment
growth-positive
Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Top Key Executive Moshe Arkin is the most upbeat insider, and their holdings increased by 15% last week
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) has significant insider ownership, with Moshe Arkin owning 51% of the company and institutions holding 27%. This suggests a vested interest in the companys expansion. The group holding the most shares stands to benefit the most if the stock rises. Insiders were the biggest beneficiaries of last week’s 15% gain. Hedge funds own 8.7% of Sol-Gel Technologies shares, indicating potential influence over management decisions. The general public holds a 14% stake in Sol-Gel Technologies.
Investment
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
growth-negative
Shareholders in Sol-Gel Technologies (NASDAQ:SLGL) are in the red if they invested five years ago
The share price of Sol-Gel Technologies has dropped 60% in the last half decade and 41% in the last year. The company has not made a profit in the last twelve months, but its revenue has grown by 25% per year in the last five years. Despite this, the share price has averaged a loss of 10% per year. Shareholders have faced a total loss of 10% per year over the past five years. Market conditions and other factors may have contributed to the poor performance. The article advises caution and highlights four warning signs for Sol-Gel Technologies.
Public Trading
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue Estimates
growth-negative
Companies Like Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Invest In Growth
Sol-Gel Technologies, a software-as-a-service business, is experiencing a significant cash burn and a decline in operating revenue. However, analysts predict that the company will break even before running out of cash. The companys cash reserves as of December 2022 were $34 million, with a cash burn of $9.7 million in the last year. Sol-Gel Technologies market capitalization is $100 million, and its cash burn represents about 9.7% of its market value. This suggests that the company could easily raise more money through issuing shares or taking on debt. Overall, while there are some concerns, the company appears to be well-capitalized and on a good path.
Investment
‘Load Up,’ Says Raymond James About These 3 ‘Strong Buy’ Stocks
Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
7 Biotech Stocks That Could Be the Next Big Thing
Sol-Gel Technologies Full Year 2022 Earnings: Misses Expectations
Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
Could The Market Be Wrong About Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Its Attractive Financial Prospects?
The Top 7 Penny Stocks to Invest in for the Long-Term
Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
growth-positive
Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
Sol-Gel Technologies Ltd. has announced the acquisition of topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome from PellePharm, Inc. The drug has been granted Orphan Drug Designation by the FDA and the EMA and has the potential to be the first-ever drug for treatment of Gorlin syndrome. Sol-Gel expects the transaction to close on or about January 30, 2023. The company estimates that SGT-610, if approved by the FDA, has the potential to generate annual net sales in excess of $300 million.
Acquisition
Zacks Industry Outlook Highlights Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies
3 Generic Drug Stocks to Watch Amid Inflation Pressures
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Sol-Gel Technologies (NASDAQ:SLGL) investors are sitting on a loss of 45% if they invested a year ago
growth-positive
Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development
Sol-Gel Technologies, Ltd., a dermatology company, has announced the appointment of Michael Glezin as Vice President, Business Development. In his new role, Glezin will be responsible for identifying new in-licensing business opportunities and potential commercial partners for the companys approved products in ex-US territories. Glezins experience in broad portfolio management and identifying new products for in-licensing as well as distributors and territories for out-licensing is expected to support Sol-Gels future growth and expand its commercial footprint beyond the U.S. market.
Management ChangesExpand
growth-positive
Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®
Sol-Gel Technologies, Ltd., a dermatology company, has announced that the FDA has approved its drug product, EPSOLAY, for the treatment of inflammatory lesions of rosacea in adults. The drug uses Sol-Gel’s proprietary microencapsulation technology and is patent protected until 2040. Sol-Gel has granted Galderma Holding SA the exclusive rights to commercialize EPSOLAY in the United States. The approval of EPSOLAY is supported by data from two positive Phase 3 clinical trials.
PartnersCustomers
growth-positive
Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®
Sol-Gel Technologies announced that TWYNEO, a topical cream for the treatment of acne vulgaris, is now available for purchase in the U.S. The cream, which contains a fixed-dose combination of tretinoin and benzoyl peroxide, was approved by the FDA in July 2021 and is being commercialized by Galderma. TWYNEO is the first and only tretinoin and benzoyl peroxide 2-in-1 combination approved by the FDA. The launch of TWYNEO has received coverage in various beauty and industry publications. Acne vulgaris is a common skin condition affecting a large percentage of the population, and TWYNEO offers a new treatment option for those affected.
Customers
growth-positive
Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA
Sol-Gel Technologies announced that its U.S. commercialization partner, Galderma, will be promoting TWYNEO Cream at the American Academy of Dermatology Annual Meeting. TWYNEO is a tretinoin and benzoyl peroxide cream for the treatment of moderate-to-severe acne. The cream utilizes microencapsulation technology to combine the two ingredients and deliver visible results in as little as two weeks. Sol-Gels CEO expressed satisfaction with the visibility and commitment of Galderma in promoting TWYNEO. Acne vulgaris affects up to 50 million people in the U.S. and can have a significant impact on quality of life. TWYNEO is the first acne treatment to combine benzoyl peroxide and tretinoin in a fixed-dose combination. Sol-Gel Technologies is a dermatology company focused on developing and commercializing topical drug products for skin diseases.
Customers
growth-positive
Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO
Sol-Gel Technologies Ltd., a clinical-stage dermatology drugs company, plans an initial public offering (IPO) of up to $86 million at a $250-350 million market value. The company develops branded and generic topical dermatological drugs for acne and Rosacea. It recently announced a successful phase 2 clinical trial for its lead product candidate, acne treatment cream TWIN. Sol-Gel was acquired by Mori Arkin in 2014 and he currently owns 100% of the shares. The company reported a net loss of $24 million for the 12-month period ending June 30, 2017, and expects the loss to continue. Sol-Gel financed its activities through loans from Arkin Dermatology Ltd.
Public Trading
growth-positive
Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million
Sol-Gel Technologies has announced a new agreement with Padagis for the transfer of its rights to two marketed generic drugs and eight unapproved generic programs. Sol-Gel will receive $21 million over 24 months and retain two generic programs with four high-value generic drug candidates. The agreement is expected to extend Sol-Gels cash runway until at least the end of 2023. Sol-Gels focus remains on supporting Galderma to launch TWYNEO® and EPSOLAY®, along with advancing its innovative pipeline of assets. The company is a dermatology company focused on identifying, developing, and commercializing branded and generic topical drug products for the treatment of skin diseases.
Partners
growth-positive
Sol-Gel Technologies Announces Closing of Additional $5.0 Million Investment
Sol-Gel Technologies has announced that its controlling shareholder, M. Arkin Dermatology Ltd., has closed an additional $5.0 million investment in the company. This brings the total gross proceeds from previous transactions to $28 million. The investment will support the companys NDA filings for its drug candidates and the commercialization of both products if approved. Sol-Gels Chairman of the Board of Directors, Mori Arkin, expressed confidence in the companys ability to provide better skincare products. The investment includes the issuance of ordinary shares and warrants to M. Arkin Dermatology Ltd. at a combined price of $11.00 per share. The warrants have an exercise price of $14.00 per share and will expire in February 2023.
Investment
growth-positive
Sol-Gel Provides Product Pipeline Updates and Anticipated Milestones for 2020
Sol-Gel Technologies, a clinical-stage dermatology company, provided a pipeline update and anticipated milestones for 2020. The company reported positive Phase 3 results for its Epsolay and Twyneo programs in 2019. Sol-Gel plans to expand its product pipeline with new pre-clinical programs for the treatment of psoriasis and other dermatological disorders. The company also provided updates on SGT-210, tapinarof, and roflumilast, which are being developed for various dermatological indications. Sol-Gel expects to submit the NDA for Epsolay in the first half of 2020 and the NDA for Twyneo in the second half of 2020. The company aims to launch its first branded tapinarof product in the U.S. in approximately 5.5 years following the approval of the originators tapinarof branded product. Sol-Gel Technologies is focused on identifying, developing, and commercializing topical drug products for the treatment of skin diseases.
Expand
growth-positive
Sol-Gel soars on acne treatment trial results
Sol-Gel Technologies announced positive results in its Phase 3 clinical trials for its acne treatment Twyneo. The company will now apply for approval for the product, which will be its first independent drug on the market. If approved, Twyneo has the potential to be the first acne vulgaris treatment to bring together benzoyl peroxide and a potent retinoid, tretinoin, in a once-daily cream. Sol-Gels share price has increased by about 90%, giving the company a market cap of $357 million. Sol-Gel previously sold its sunscreen products to Merck for $10 million in order to focus on pharmaceuticals.
Customers
growth-positive
Sol-Gel inks new deal with Perrigo for antibiotic foams;shares ahead 2% (NASDAQ:SLGL)
Sol-Gel Technologies has entered into a collaboration agreement with Perrigo for the development, manufacture, and commercialization of two new generic antibiotic foams. The agreement involves sharing development costs and gross profits, with Sol-Gel pursuing regulatory approval in the U.S. and Perrigo handling commercialization. The financial terms of the agreement were not disclosed.
Partners
Sol-Gel Technologies Announces Collaborative Agreement for Generic Product with Perrigo Sol-Gel
growth-positive
Sol-Gel Technologies Ltd. Announces Pricing of Initial Public Offering
Sol-Gel Technologies Ltd., a clinical-stage dermatology company, has announced the pricing of its initial public offering (IPO) of 6,250,000 ordinary shares at a price of $12.00 per share. The IPO is expected to raise aggregate proceeds of $75.0 million. The company has granted the underwriters a 30-day option to purchase up to an additional 937,500 ordinary shares. The closing of the IPO is expected to occur on or about February 5, 2018. Sol-Gels ordinary shares have been approved for listing on The Nasdaq Global Market and are expected to begin trading under the symbol SLGL on February 1, 2018.
Public Trading
growth-positive
Sol-Gel sets terms for $60m Nasdaq IPO
Dermatological company Sol-Gel has begun its roadshow for a Nasdaq IPO scheduled for January 31. The company plans to raise $60 million at a $11-13 per share, reflecting a company value of $250 million. $25 million has already been guaranteed for parties who expressed interest in advance. Sol-Gels leading product is a non-antibiotic treatment for acne, which has shown promising results in Phase II trials. The company also has other products in development, including a treatment for rosacea. Sol-Gel is developing generic products in partnership with Perrigo Company. Sol-Gels owner, Mori Arkin, is also a shareholder in UroGen Pharma and plans to bring another company, Exalenz Bioscience, to Nasdaq this year.
Public TradingInvestment
growth-positive
Sol-Gel Technologies mulls Nasdaq IPO
Sol-Gel Technologies, a drug developer that specializes in nano-metric particles for dermatological diseases, is considering a Nasdaq IPO. The company is planning to raise $40-50 million at a company value of $150 million. Sol-Gel was acquired by Arkin Holdings for $10 million last year. The company has previously raised $26 million from investors such as Argonaut, Challenge Fund - Etgar, and Jerusalem Venture Partners. Sol-Gels products include treatments for rosacea, acne, psoriasis, and athletes foot. The companys unique technology allows drugs to penetrate the skin more easily and enables the combination of various medications in a single lotion. The biomedical industry has seen success in the first half of 2015, with many companies making successful flotations on Nasdaq.
Investment
growth-positive
Mori Arkin in talks to acquire Sol-Gel
Sol-Gel, a company developing skincare products using nanotechnology, is in talks to be acquired by businessman Mori Arkin for $10 million. Sol-Gel has developed a unique wrapping technology using nanoscale particles to improve the performance of drugs. The companys lead products are a rosacea treatment and an acne treatment, both in clinical trials. Sol-Gel has received $26 million in investments from Israeli and foreign venture capital firms. In 2008, the company sold some of its sun-protection technology to Merck & Co. for $10 million. The investors in Sol-Gel are considering accepting Arkins offer. Arkin has previously invested in the field of dermatology and has been investing in biomed and other fields since selling his company, Agis, for $900 million.
InvestmentAcquisition
Sol-Gel Technologies Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 48 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Sol-Gel Technologies Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 512544693 |
| Crunchbase | sol-gel-technologies |
| Phone | +97289313433 |
| Creator | Rachel Wain |
| Creator email | rachelwain18@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-01-10T00:00:00.000Z |
| Created | 2014-11-30T00:00:00.000Z |
| Status detail | Acquired by Mori Arkin on Jul, 2014 |